中文Vientiane, Laos - August 01 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that TAZEMETOSTAT have been approved by the Ministry of Health of Laos.
Approved drugs are:
Tazemetostat oral tablets: sold under the brand name TAZEDX.
Tazemetostat is an inhibitor of histone-lysine N-methyltransferase EZH2. By inhibiting EZH2, it can inhibit the methylation of histone H3 lysine 27 (H3K27), restore the expression of tumor suppressor genes, and allow B cells to continue to differentiate or produce cytotoxicity, thereby controlling tumor growth.
Tazemetostat is currently approved for the treatment of epithelioid sarcoma and follicular lymphoma.
Laos Reg No.: 07L1139/24
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.